Disseminated fungal infection in a patient receiving zanubrutinib.

We report a case of fatal disseminated aspergillosis in the setting of administration of zanubrutinib, a second-generation Bruton's tyrosine kinase inhibitor thought to have a lower rate of immunosuppression-related side effects.